Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult 40 to 75 years of age~2. Existing hypertension that is being treated using pharmacological therapy with a single agent that is not a calcium channel blocker~3. SBPday \> 135 and ≤ 169 mmHg and average daytime (9:00 to 21:00) ambulatory diastolic blood pressure (DBPday) ≤ 110 mmHg at Day 0 (after the 10- to 14-day washout from prior blood pressure medication)~4. Body Mass Index of 18.5 to 34.9 kg/m2~5. Healthy (other than hypertension) as determined by the Investigator based on medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and clinical laboratory tests~6. A negative pregnancy test at initial screening visit~7. If woman of childbearing potential, agree to use a highly effective form of birth control while on study (from Screening through final study visit)~8. Able to comprehend and sign an informed consent form.~Exclusion Criteria:~1. Resting SBP \> 169 mmHg or a resting DBP \> 110 mmHg at initial screening visit while on their standard antihypertensive therapy (where resting is defined as supine for at least 10 minutes with minimal interaction)~2. Weight \< 55 kg~3. Fragile health~4. Evidence of clinically significant findings on screening evaluations (clinical, laboratory, and ECG) which, in the opinion of the Investigator would pose a safety risk or interfere with appropriate interpretation of safety data~5. Current or recent history (within four weeks prior to initial screening visit) of a clinically significant bacterial, fungal, or mycobacterial infection~6. Current clinically significant viral infection~7. History of malignancy, with the exception of cured basal cell or squamous cell carcinoma of the skin~8. Major surgery within four weeks prior to initial screening visit~9. Presence of a malabsorption syndrome possibly affecting drug absorption (e.g., Crohn's disease or chronic pancreatitis)~10. Active peptic ulceration or history of gastrointestinal bleeding~11. History of myocardial infarction, congestive heart failure, or stroke~12. Any current cardiovascular disease (other than hypertension)~13. History of psychotic disorder~14. History of alcoholism or drug addiction or current alcohol or drug use that, in the opinion of the Investigator, will interfere with the subject's ability to comply with the dosing schedule and study evaluations~15. History of any illicit drug use within one year prior to initial screening visit~16. Positive drug screen at initial screening visit. A positive drug screen for opiates only (with all other drug tests negative) will not be a basis for exclusion if the subject took over-the-counter narcotics as indicated on the product label within 24 hours prior to the drug screen~17. Current treatment or treatment within 30 days prior to first dose of study drugs with another investigational drug or current enrollment in another clinical trial~18. Known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C~19. Known hypersensitivity to amlodipine or celecoxib~20. Known hypersensitivity to the inactive ingredients in the over-encapsulated (OE) study drugs~21. Asthma, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic type reactions after taking acetylsalicylic acid or NSAIDs including cyclooxygenase-2 inhibitors~22. Subjects who, in the opinion of the Investigator, are unable or unlikely to comply with the dosing schedule and study evaluations~23. Pregnant or lactating~24. Unable to correctly use ambulatory blood pressure monitor after instruction on its use~25. Subjects with Child-Pugh Class B or C cirrhosis~26. Subjects currently taking a calcium channel blocker or any NSAID for any reason will be excluded. Subjects will not be withdrawn from these drugs to be enrolled in the trial~27. Subjects that took a calcium channel blocker in the past for any indication~28. Creatinine clearance \< 50 ml/min as estimated by the Cockroft-Gault equation~29. Known cytochrome P450 2C9 poor metabolizer~30. Subjects with allergy or hypersensitivity to sulfonamides

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Amlodipine+Celecoxib (Type: EXPERIMENTAL): OE 10 mg amlodipine besylate tablet + OE 200 mg celecoxib capsule qd for 14 days
- Amlodipine+Placebo (Type: ACTIVE_COMPARATOR): OE 10 mg amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days
- Placebo+Placebo (Type: SHAM_COMPARATOR): Matched placebo for OE amlodipine besylate tablet + matched placebo for OE celecoxib capsule qd for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete